Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension

Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.

Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension in the United States of America (MOMENTUM).’ The study aims to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN). This research is significant as it could reveal important insights into the relationship between eHC and rHTN, potentially leading to better management strategies for affected patients.

The study is non-interventional, meaning it does not involve any active treatment or intervention. Instead, it focuses on observing and collecting data from approximately 1000 patients across 45 sites in the United States. The process includes initial screening, lab tests, and follow-up visits to gather comprehensive data on cortisol levels and medical history.

This observational study follows a cohort model with a cross-sectional time perspective. It involves multiple visits for data collection, including blood draws and a CT scan for patients identified with eHC. The primary purpose is to gather observational data to understand the prevalence and implications of eHC in rHTN patients.

The study began on January 30, 2025, with the latest update submitted on August 25, 2025. These dates are crucial as they indicate the study’s progress and timeline for data collection and analysis.

For investors, this study could impact Corcept Therapeutics’ stock performance and investor sentiment, as positive findings might enhance the company’s reputation in the medical field. The study’s outcomes could also influence the broader industry, especially if they lead to new treatment approaches for rHTN linked to eHC.

The study is currently ongoing, and further details can be accessed on the ClinicalTrials portal.